X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.12−0.05 (-1.58%)
Close on Nov 13, 2026Market cap $309.34MP/E –Yield –
X4 Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
X4 Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was -813.3%. For fiscal 2025 it was -1218.4%, against -1440.4% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1218.4% | +221.9 |
| FY2024 | Dec 31, 2024 | -1440.4% | +630.6 |
| FY2020 | Dec 31, 2020 | -2071.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -721.4% | +1142.1 |
| Q2 FY2026 | Jun 30, 2026 | -673.2% | +841.0 |
| Q1 FY2026 | Mar 31, 2026 | -809.6% | −841.0 |
| Q4 FY2025 | Dec 31, 2025 | -1087.5% | +1567.2 |
| Q3 FY2025 | Sep 30, 2025 | -1863.4% | +4689.4 |
| Q2 FY2025 | Jun 30, 2025 | -1514.2% | −17647.9 |
| Q1 FY2025 | Mar 31, 2025 | 31.3% | +402.6 |
| Q4 FY2024 | Dec 31, 2024 | -2654.7% | −2387.4 |
| Q3 FY2024 | Sep 30, 2024 | -6552.9% | – |
| Q2 FY2024 | Jun 30, 2024 | 16133.7% | – |
| Q1 FY2020 | Mar 31, 2020 | -371.3% | – |
| Q4 FY2018 | Dec 31, 2018 | -267.4% | – |
See a number that looks wrong?